Zyprexa (olanzapine) is not classified as a mood stabilizer. It’s an atypical antipsychotic. But the distinction is blurrier than it sounds, because Zyprexa is FDA-approved to treat many of the same conditions that traditional mood stabilizers like lithium target, including acute mania, mixed episodes, and long-term maintenance of bipolar I disorder. In practice, many psychiatrists prescribe it alongside or instead of traditional mood stabilizers for bipolar disorder.
How Zyprexa Is Officially Classified
The term “mood stabilizer” traditionally refers to medications like lithium and valproate that were specifically developed to even out the highs and lows of bipolar disorder. Zyprexa belongs to a different drug class: second-generation (atypical) antipsychotics. These medications were originally designed to treat psychotic symptoms like hallucinations and delusions, primarily in schizophrenia.
However, the FDA has approved Zyprexa for several bipolar-related uses that overlap heavily with what mood stabilizers do. Specifically, it’s approved for acute manic or mixed episodes (both alone and combined with lithium or valproate), and for ongoing maintenance treatment of bipolar I disorder. For bipolar depression, it’s approved only in combination with fluoxetine (an antidepressant), not on its own. So while the label says “antipsychotic,” the approved uses look a lot like a mood stabilizer’s job description.
How It Works in the Brain
Zyprexa affects a wide range of chemical messenger systems in the brain. It blocks dopamine receptors, which helps calm the racing thoughts, impulsivity, and elevated energy of mania. It also blocks certain serotonin receptors, which is thought to contribute to its mood-stabilizing effects and may help reduce depression when combined with other medications. This broad receptor profile is one reason it can address multiple phases of bipolar disorder rather than just one.
Traditional mood stabilizers like lithium work through entirely different mechanisms, affecting signaling pathways inside brain cells rather than blocking specific receptors. This is part of why the two classes are kept separate in classification, even though they can produce similar clinical results.
How It Compares to Lithium for Mania
In head-to-head trials, Zyprexa has performed well against lithium for acute mania. A four-week randomized trial comparing the two found that patients on olanzapine showed significantly greater improvement in mania scores than those on lithium. About 91% of olanzapine patients completed the study, compared to 79% on lithium.
Atypical antipsychotics like Zyprexa also tend to work faster than lithium. In treating acute mania in both children and adults, these medications have a more rapid onset of action. Lithium can take six to seven weeks to reach full effect in younger patients, while antipsychotics typically begin reducing symptoms sooner. That speed advantage makes Zyprexa a common choice when someone is in the middle of a severe manic episode and needs quick stabilization.
Long-Term Use for Bipolar Maintenance
Where mood stabilizers have traditionally dominated is in keeping people stable over months and years. Zyprexa has shown it can do this too, though with trade-offs. In a 48-week maintenance trial, patients on olanzapine had a relapse rate of 46.7%, compared to 80.1% on placebo. The median time before relapse was 174 days on olanzapine versus just 22 days on placebo.
Those numbers show meaningful protection against relapse, but a 47% relapse rate over a year is still substantial. Lithium is generally considered the safest and most effective option for long-term adult maintenance, particularly for preventing both manic and depressive episodes. In practice, many people end up on a combination of a traditional mood stabilizer and an atypical antipsychotic like Zyprexa, especially if one medication alone doesn’t provide enough control.
Bipolar Depression: Only in Combination
One important limitation of Zyprexa is that it doesn’t treat bipolar depression on its own. The FDA specifically notes that olanzapine monotherapy is not indicated for depressive episodes. However, when combined with fluoxetine (sold together as the brand-name drug Symbyax), it was actually the first medication the FDA ever approved specifically for bipolar depression.
The combination is effective. In a meta-analysis of four randomized trials covering over 1,300 patients, the olanzapine-fluoxetine combination nearly doubled the likelihood of response compared to placebo. For every four patients treated, one additional patient responded who wouldn’t have on placebo. This is a meaningful effect, and it’s one reason why Zyprexa remains part of bipolar treatment plans even though it can’t handle depression alone.
Weight Gain and Metabolic Side Effects
The biggest drawback of Zyprexa, and the main reason it’s not always a first-line choice despite its efficacy, is weight gain. Among all antipsychotics, olanzapine is one of the most likely to cause significant weight increases. In a meta-analysis of patients with early-phase psychosis, the average weight gain was about 5.5 kilograms (roughly 12 pounds) in the first 13 weeks. In studies lasting longer than 13 weeks, average weight gain climbed to 11.35 kilograms, or about 25 pounds.
In the head-to-head trial against lithium, significantly more olanzapine patients gained 7% or more of their baseline body weight. Beyond the number on the scale, long-term weight gain raises concerns about diabetes, high cholesterol, and cardiovascular risk. Interestingly, the metabolic changes in blood sugar and lipids observed in studies were generally small and didn’t correlate directly with the amount of weight gained, but the weight itself remains a serious consideration for anyone taking this medication over months or years.
Sedation is another common side effect. Zyprexa tends to cause more drowsiness than lithium, which can be useful during an acute manic episode when someone hasn’t slept in days, but becomes a burden during maintenance treatment when alertness matters for daily life.
Why the Label Matters Less Than You Think
The distinction between “mood stabilizer” and “atypical antipsychotic” is more about how the drug was developed and classified than about what it actually does in clinical practice. Zyprexa stabilizes mood in bipolar disorder. It treats mania, prevents relapse, and (with fluoxetine) addresses bipolar depression. By functional criteria, it does what mood stabilizers do.
The reason the classification still matters is practical: it signals different side effect profiles and monitoring needs. Traditional mood stabilizers like lithium require blood level monitoring but carry less metabolic risk. Zyprexa doesn’t need blood level checks but requires close attention to weight, blood sugar, and cholesterol. Your prescriber’s choice between these options depends on which phase of bipolar disorder needs treatment, how quickly symptoms need to come under control, and which side effects are most acceptable for your situation.